Contact Us

Atypical Antipsychotic Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Which atypical antipsychotic drug(s) did the patient take?

What condition was this medication prescribed to treat?

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Parker & Waichman Files Claims Against Eli Lilly and Company on Behalf of Three Individuals Claiming Injuries Caused by Zyprexa; Plaintiffs Diagnosed with Serious Cases of Diabetes and Pancreatitis

Additional Claims vs. Eli Lilly & Co. Expected to be Filed

Mar 19, 2004 | PRNewswire

Parker & Waichman LLP ( filed claims against Eli Lilly and Company (NYSE: LLY - News) on behalf of three individuals who claim to have sustained severe side-effects from Zyprexa. The claims were filed in Federal District Court in the Eastern District of New York. Two plaintiffs have been diagnosed with serious cases of diabetes, and another plaintiff has required lengthy intensive care hospitalization due to a diagnosis of acute pancreatitis. Zyprexa is currently the most popular atypical antipsychotic medication, and is Eli Lilly and Company's best-selling pharmaceutical. Zyprexa users can visit for more information on these claims.

The British Medical Control Agency and the Japanese Health and Welfare Ministry have both warned about the risk of diabetes in patients who are prescribed Zyprexa. In 2002, a study at Duke University showed a connection between Zyprexa and diabetes. This study documented nearly 300 cases of diabetes in people using Zyprexa. Only recently has Eli Lilly and Company added some language to their labeling in the United States concerning the risk of diabetes from Zyprexa.

"We are confident that we will bring justice to our clients whose lives have been permanently affected by the side-effects of a drug that provides little efficacious benefit, but causes life-threatening injuries," commented Jerrold S. Parker, Co-Founder of Parker & Waichman.

"With the alarming studies that have been conducted and the warnings from national health agencies about Zyprexa's link to blood sugar disorders, it is appalling that Eli Lilly has not issued adequate warnings and that they continue to market this drug heavily directly to consumers."

Zyprexa was approved for the treatment of schizophrenia in 1996 and for the treatment of bipolar mania in 2000. It is part of a new generation of antipsychotics known as atypicals, which include Seroquel, Risperdal, Abilify, Clozaril, and Geodon. Ironically, the primary advantage of the newer atypical antipsychotic medications was supposed to be a lower incidence of side effects than the conventional antipsychotics introduced in the 1950s (Haldol, Thorazine, Prolixin, Navane, Stelazine, Trilafon, and Mellaril).

More information on Zyprexa side-effects is available at Parker & Waichman's Zyprexa website Current and former Zyprexa users can visit this to request a free legal evaluation.

For more information on Parker & Waichman, LLP please visit or call 1-800-YOURLAWYER. Current and former shareholders are also encouraged to visit


Parker & Waichman, LLP
1-800-YOURLAWYER (1-800-968-7529)

Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo